Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • Targeted Therapy in BRCA/PALB2-Mutated ER+/HER2- Breast Cancer: Insights from TBCRC 056

    At SABCS 2024, Dr. Erica Mayer presented findings from the TBCRC 056 Phase II trial, which investigated the combination of the PARP inhibitor niraparib and anti-PD-1 therapy dostarlimab in neoadjuvant…

    2025.02.21
  • New Phase 3 Data on Rilzabrutinib for Immune Thrombocytopenia (ITP) – LUNA 3 Trial

    Published in Blood and presented at ASH 2024, the LUNA 3 study evaluates the efficacy and safety of rilzabrutinib, an oral Bruton Tyrosine Kinase Inhibitor (BTKi), in patients with previously…

    2025.02.21
  • Insights from the MVA-MERS-S Vaccine Trial

    A phase 1b clinical trial by a valuable team of researchers explores the safety, immunogenicity, and optimal dosing of MVA-MERS-S, a modified vaccinia Ankara-based candidate vaccine for MERS-CoV.

    2025.02.21
  • Gut Microbiota and Eating Disorders: A New Frontier in Neuroinflammation Research

    Could the gut microbiome be the missing link in understanding eating disorders? A groundbreaking study led by Dr. Sabrina J.P. Huwart, Dr. Nuria Morales-Puerto, and Dr. Amandine Everard (Université catholique de Louvain) sheds light on the interplay between gut microbiota, neuroinflammation, and food reward alterations—a critical factor in the development of eating disorders like anorexia…

    2025.02.21
  • Enhancing PrEP Adherence Among Young Women in Johannesburg: What Works?

    Adherence to HIV pre-exposure prophylaxis (PrEP) remains a challenge among young women in sub-Saharan Africa, despite its proven effectiveness in preventing HIV. A landmark study led by Dr. Jennifer Velloza (University of California, San Francisco) evaluates innovative interventions to improve PrEP adherence in Johannesburg, South Africa.

    2025.02.21
  • New 10-Year Follow-Up Data from the DREPAGREFFE Trial: Allogeneic Stem Cell Transplantation vs. Standard Care in Sickle Cell Anemia

    Recently published in Blood, the DREPAGREFFE-2 trial provides crucial insights into long-term cognitive and cerebrovascular outcomes in children with sickle cell anemia (SCA) and a history of abnormal cerebral velocities.…

    2025.02.21
  • New Insights into LDH-A and T Cell Differentiation

    A recent study published in Blood (Volume 144, Supplement 1, November 5, 2024) explores the role of Lactate Dehydrogenase A (LDH-A) in CD8+ T cell differentiation and its impact on…

    2025.02.21
  • New Insights from SABCS 2024: Biomarkers and Pembrolizumab in TNBC

    At the San Antonio Breast Cancer Symposium (SABCS) 2024, Joyce O’Shaughnessy presented findings from the KEYNOTE-522 trial, a phase 3 study evaluating pembrolizumab in combination with chemotherapy for early-stage triple-negative…

    2025.02.21
«previous next»
Recent Posts
  • Blood × Immunology: Six Leading Chinese and French Experts Discuss Frontiers, Breakthroughs, and Clinical Translation | 2026 China-France Scientific Symposium on Hematology and Immunology
  • CSCO 2026 Debate | Professors Wenyan Chen and Tengfei Chao: Should Immunotherapy Be Combined with Chemotherapy or an ADC in First-Line Treatment of Advanced TNBC?
  • CSCO 2026 | Professor Hong Bu: Standardizing Breast Pathology Diagnosis Requires “Knowing, Understanding, and Applying the Standards,” While Digital and Intelligent Transformation Must Address Clinical Pain Points
  • CSCO 2026 | Professor Chunfang Hao: ADCs Are Expanding Across the Breast Cancer Treatment Continuum, Advancing From Later Lines to First-Line Therapy and From Monotherapy to Combination Regimens
  • CSCO 2026 | Professor Yanxia Shi: Early Intervention Guided by ctDNA and Dual-Target ADC Innovation Are Reshaping Precision Breast Cancer Treatment
Recent Comments
    Archives
    • October 2026
    • September 2026
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top